- 24/7 Wall St.•3 hours ago
In a time when government wrangling about drug prices is more than commonplace, news of a biosimilar for the mega-blockbuster Humira being approved took the backseat to many other things.
- Zacks•4 hours ago
Amgen, Inc. (AMGN) today announced the approval of Amjevita (adalimumab-atto), a biosimilar version to AbbVie Inc.'s (ABBV) rheumatoid arthritis (RA) drug Humira.
- The Wall Street Journal•3 days ago
U.S. regulators approved Amgen Inc.’s copy of the AbbVie Inc.’s anti-inflammatory treatment, Humira, which was the second-biggest selling drug in 2015.
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||173.84 x 200|
|Ask||173.89 x 100|
|Day's Range||173.14 - 174.42|
|52wk Range||130.09 - 176.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.76|
|Avg Vol (3m)||2,864,382|
|Dividend & Yield||4.00 (2.29%)|